drugset
drugset / Trial / NCT03254966

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

NCT03254966 ↗

Phase 2 Completed 194 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to severe active rheumatoid arthritis.

Timeline

Start
2017-11-24
Primary completion
2019-04-16
Completion
2019-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302 Unknown — Oral

Indications

rheumatoid arthritis